[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587863":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":45,"collaborators":19,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":19,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":19,"enrollmentInfo":56,"targetDuration":19,"studyType":59,"phases":60,"briefSummary":63,"conditions":64,"keywords":19,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Wuhan Createrna Science and Technology Co., Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MY008211A tablets","EXPERIMENTAL","MY008211A tablets 400mg BID",[13],"Drug: MY008211A tablets",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Participants will receive MY008211A at a dose of 400 mg orally b.i.d",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Wuhan Createrna Science and Technology Co.,Ltd","CONTACT","027-68788900","lcyxzx@createrna.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Chinese Academy of Medical Sciences Hematology Hospital (Institute of Hematology, Chinese Academy of Medical Sciences)","RECRUITING","Tianjin","Tianjin Municipality","300020","China","CN",{"type":36,"coordinates":37},"Point",[38,39],117.17667,39.14222,{"lat":39,"lon":38},[42],{"name":43,"role":23,"phone":44,"phoneExt":19,"email":19},"Fengkui Zhang, PhD","022-23909095",{"type":46,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100587863","phase-2-long-term-safety-and-tolerability-of-my008211a-tablets-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-100587863",false,"NCT06933914","Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria","An Open Label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of MY008211A Tablets in Patients With PNH Paroxysmal Nocturnal Hemoglobinuria (PNH)","Inclusion Criteria:\n\n1. Patients who have previously received and completed MY008211A study treatment, and are judged by the investigator to have treatment benefit and may benefit from continued treatment of MY008211A.\n2. Prior vaccinations against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae infections.\n\nExclusion Criteria:\n\n1. History of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus.\n2. Known or suspected hereditary complement deficiency.\n3. Any comorbidity or medical condition (including but not limited to any active systemic bacterial, viral or fungal infection or malignancy) that, in the opinion of the investigator, could put the subject at increased risk or potentially confound study data.","ALL","18 Years",{"count":57,"type":58},120,"ESTIMATED","INTERVENTIONAL",[61,62],"PHASE2","PHASE3","This is a multicenter, single-arm, open-label study to characterize long-term safety and tolerability of MY008211A tablets and to provide access to MY008211A tablets to patients with PNH who have completed Phase 2 or 3 studies with MY008211A tablets.",[65],"Paroxysmal Nocturnal Hemoglobinuria (PNH)","2025-04-11",{"date":68,"type":69},"2025-04-18","ACTUAL",{"date":71,"type":69},"2024-11-30",{"date":73,"type":58},"2026-12-30",{"name":5,"class":6},1]